Barbier brings nearly 20 years of drug discovery and development experience to Translate Bio, and will be responsible for leading all clinical research and development, medical affairs, and related functions at Translate Bio.
Prior to joining Translate Bio, Barbier was vice president of clinical development, rare genetic diseases, at Agios Pharmaceuticals, where she led the development program of a small molecule in rare benign hematological diseases.
Previously, Barbier spent seven years at Shire, most recently as global clinical development lead and senior medical director, where she worked on a variety of rare genetic diseases including lysosomal storage diseases and hereditary angioedema. Her prior experience includes positions at Envivo, Johnson and Johnson and Aventis.
During her career, Barbier has made significant contributions to several approved products such as Elaprase (Hunter syndrome), Aubagio (multiple sclerosis) and Firazyr (hereditary angioedema), and has led several investigational new drug applications for new chemical entities.
Barbier received her M.D. and Ph.D. in pharmacology from the University of Gent, Belgium, and a Master of Science from the Free University of Brussels, Belgium. She pursued a postdoctoral fellowship at the University of Tennessee in Memphis.
Translate Bio is focused on the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases.
The company's RNA platforms for powering endogenous therapeutic protein production is applicable to a broad range of diseases caused by insufficient protein production, including rare diseases of the liver, lung, and central nervous system.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference